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Primary immunodeficiency diseases (PIDs) include over 250 diverse disorders. The cur-
rent study assessed management of PID by family practice physicians. The American 
Academy of Allergy, Asthma, and Immunology Primary Immunodeficiency Committee 
and the Immune Deficiency Foundation conducted an incentivized mail survey of family 
practice physician members of the American Medical Association and the American 
Osteopathic Association in direct patient care. Responses were compared with 
subspecialist immunologist responses from a similar survey. Surveys were returned 
by 528 (of 4500 surveys mailed) family practice physicians, of whom 44% reported 
following ≥1 patient with PID. Selective immunoglobulin A deficiency (21%) and chronic 
granulomatous disease (11%) were most common and were followed by significantly 
more subspecialist immunologists (P < 0.05). Use of intravenously administered immu-
noglobulin and live viral vaccinations across PID was significantly different (P < 0.05). 
Few family practice physicians were aware of professional guidelines for diagnosis 
and management of PID (4 vs. 79% of subspecialist immunologists, P < 0.05). Family 
practice physicians will likely encounter patients with PID diagnoses during their career. 
Differences in how family practice physicians and subspecialist immunologists manage 
patients with PID underscore areas where improved educational and training initiatives 
may benefit patient care.
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inTrODUcTiOn
Primary immunodeficiency diseases (PIDs) comprise more than 250 heterogeneous disorders (1). 
These diseases are caused by intrinsic defects in the immune system that lead to aberrant immune 
responses (2). The field of PID has evolved, and the number of recognized disorders has rapidly 
increased (3–5), creating challenges for maintaining up-to-date disease classifications and for dis-
seminating practical patient management guidelines.
A recent analysis of registry data and epidemiologic surveys estimated that as many as six 
million people worldwide are living with PID, with the majority undiagnosed (27,000 patients 
identified from national registries; 60,000 patients identified from the Jeffrey Modell Centers 
Network) (3). A prior household random-digit dialing telephone survey indicated that as 
many as 150,000–360,000 persons in the United States have been diagnosed with a PID (6). 
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Precise data on prevalence are unavailable at least in part 
because of the heterogeneity of this group of diseases, lack of 
newborn screening (4, 6), and the growing number of recog-
nized immunodeficiency diseases (3–5). The 2007 telephone 
survey indicated that these diseases impact an estimated 1 in 
1200 United States persons (6). These data suggest that PID 
prevalence is likely underestimated, indicating most physicians 
are likely to encounter patients with PID over the duration of 
their practicing careers. Expanded appreciation of the preva-
lence of these diseases (6–9) has been accompanied by improved 
recognition and diagnostic testing (10–12), particularly with 
ongoing initiatives to promote recognition and guidelines for 
the care of patients with PID (1, 13–17).
Early recognition and diagnosis of PID is important for patient 
prognosis and quality of life (18). However, PID is generally not 
detected until after a patient has experienced repeated infections. 
Currently, the time between onset of symptoms and treatment 
may be as long as 12 years (19). During this intervening period, 
recurrent infections and improperly managed disease may lead 
to morbidity and mortality and upper and lower airway infec-
tions that may cause pulmonary complications and eventual 
terminal lung disease (18, 20–22). Therefore, the ultimate goal 
is to identify patients with PID prior to the onset of clinical 
symptoms.
Primary care physicians (PCPs) are usually the front-line 
health-care providers with whom patients first consult with 
health issues and are therefore the first physicians to treat infec-
tions and other symptoms arising in patients with undiagnosed 
PID. Earlier recognition of signs of an underlying PID may 
lead to earlier referral to an immunologist, reducing time to 
diagnosis and initiation of treatment. However, the recognition 
of cases within such diverse and numerous subclassifications of 
disease can be a challenge for physicians who do not specialize 
in immunology. Family practice physicians comprise a primary 
care specialty that provides comprehensive care to both adult and 
pediatric patients. Further understanding of the medical training 
and practice among family practice physicians with regards to the 
diagnosis and treatment of PID may reveal areas for educational 
initiatives to improve awareness and ultimately identification of 
patients with the disease.
Joint efforts of the American Academy of Allergy, Asthma, and 
Immunology (AAAAI) Primary Immunodeficiency Committee 
and the Immune Deficiency Foundation (IDF) have allowed 
for numerous surveys to gain understanding of how physicians 
diagnose, manage, and treat patients with PID (23–26). These 
have provided insights into typical clinical approaches in an area 
that has historically been the domain of a small number of leading 
experts.
The primary goal of the current survey was to gain insight 
into the practice of family practice physicians in order to identify 
opportunities for improvements regarding the diagnosis and 
management of patients with PID likely encountered over the 
course of their clinical practice. The objectives of the current 
study were to report family practice physician responses to the 
PID survey and to compare them with responses from a previous 
survey of subspecialist immunologists.
MaTerials anD MeThODs
survey subjects
We conducted a survey among members of the American Medical 
Association and the American Osteopathic Association. Family 
practice physicians in direct patient care were eligible to take part 
in the survey and were mailed a four-page questionnaire.
At the time of this study, the team did not seek a full ethics, 
Internal Review Board (IRB) determination for need for over-
sight. However, this study does meet the criteria listed in 45 CFR 
46.101(b), Category: research involving the use of educational 
tests, survey procedures, interview procedures, or observation of 
public behavior, and hence would be exempt for the need for IRB 
oversight.
survey Design and administration
The survey questionnaire (http://primaryimmune.org/wp-
content/uploads/2015/01/Family-Practice_qx.pdf) was origi-
nally developed through collaboration of the AAAAI Primary 
Immunodeficiency Committee and the IDF to gain understand-
ing of the scope of PID practice (23). The aim of this study was 
to use this instrument to evaluate family practice physician 
understanding related to recognition and diagnosis of PID. The 
survey collected information on primary patient care settings, 
number of PID diagnoses followed, awareness of PID identifica-
tion testing and treatment strategies, use of immunoglobulin (Ig) 
replacement therapy, hygiene-based interventions, and vaccina-
tion recommendations. The four-page, self-administered survey 
was anonymous.
Physician sampling (names and addresses) was purchased 
from an American Medical Association Physician Masterfile of 
physicians identified as family practitioners. The first mailing 
occurred on September 15, 2009 and the second mailing, which 
was sent to previous non-responders, was on October 23, 2009. 
Data collection was completed in January 2010. A US$25 incen-
tive (from the IDF) was offered to physicians who completed the 
survey.
Data analysis
Only physicians who self-identified their specialty as family 
medicine (including family medicine whether they focus upon 
children, adults, or both) were included in the analysis. Returned, 
completed surveys determined the analysis population.
statistical/Other analyses
Survey responses were collected and a descriptive analysis was 
carried out for all survey questions. For some data sets, family 
practice physician responses were compared with responses to 
a previous survey of allergist/immunologist members of the 
AAAAI who devote >10% of their practice to patients with PID 
and are therefore considered “subspecialist immunologists” or 
“focused” immunologists (23). A separate statistical analysis of 
those responses was carried out using χ2 and Fisher’s exact tests. 
A P value of <0.05 was considered significant. Analysis was con-
ducted using PASW Statistics 18 (SPSS Inc., an IBM Company, 
Chicago, IL, USA).
TaBle 1 | Demographics of respondents.
characteristic Family practice 
physicians
(N = 528)
subspecialist 
immunologists
(N = 71)
Year of graduation
≥1990, n (%) 246 (48) 18 (25)
1975–1989, n (%) 219 (43) 28 (39)
≤1974, n (%) 44 (9) 25 (35)
Missing, n (%) 5 (1) 0 (0)
Mean 1987 1978
Training,a  n(%)
Family medicine (adults and children) 469 (89) NA
Family medicine (adults) 33 (6) NA
Other b 21 (4) NA
Family medicine, pediatrics 4 (1) NA
Primary patient care setting,c  n(%)
Single-specialty group 217 (41) 9 (13)
Multispecialty group 102 (19) 6 (8.5)
Solo practice 105 (20) 4 (6)
Hospital outpatient 29 (6) 41 (58)
HMO 12 (2) 0 (0)
Otherd 60 (12) 7 (10)
PiD coverage in medical school,e  n(%)
“Only a little” 399f/526 (76) NA
“Adequately” 63f/526 (12) NA
“Not at all” 61f/526 (11) NA
“Very well” 3f/526 (1) NA
HMO, health maintenance organization; NA, not applicable; PIDs, primary 
immunodeficiency diseases.
aOne respondent did not provide information about primary specialty.
bAnswers given for other includes acupuncture, anesthesia residency, care of the 
developmentally disabled, critical care medicine, deployment medicine (army), 
emergency medicine, geriatrics, holistic medicine, hospitalist, musculoskeletal 
medicine, obstetrics–gynecology, occupational medicine, sports medicine, student 
health, and urgent care.
cThree respondents did not provide information about primary patient care setting.
dAnswers given for other includes academic outpatient, blank (no response),  
college/university health center, community health-care clinic (including community 
outpatient, clinic, and urgent care), corporate primary care (including workers comp), 
correctional facility, education (including faculty, teaching medical school, residency 
program, residency clinic, and residency faculty group), emergency medicine, federally 
funded health center (including federally qualified health center and federally qualified 
rural health center), free clinics for the poor, health intervention services clinic, health 
department, health policy, hospital outpatient, locum tenens, military (including veterans 
affairs clinic, military/federal contractor, veteran’s medical affairs, military base clinic, 
military outpatient clinic, and Tricare), no ambulatory, no outpatient work, nursing home, 
psychiatric hospital, skilled nursing facility, small practice (two physicians),  
state development center, and urgent care clinic.
eQuestion in survey was “How fully were primary immunodeficiency diseases covered 
in medical school?”
fN = 526.
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resUlTs
survey response
Of the 4500 surveys mailed, 528 completed surveys were returned 
[14 respondents were excluded from the analysis (5 saw “0” 
patients on an outpatient basis; 9 failed to answer the question 
asking how many patients they saw on an outpatient basis)]. A 
12% response rate is similar to the rate achieved in a prior survey 
that assessed PID management among subspecialist allergist/
immunologist members of AAAAI (23). Although these response 
rates may be low, they likely represent the general understanding 
that PIDs are a rare group of diseases.
Demographics of survey respondents
The majority (89%) of respondents reported a primary specialty 
of family medicine and 41% reported being a part of a single-
specialty group (Table  1). Approximately half (48%) reported 
graduating from medical school in 1990 or later; the mean year 
of graduation was 1987. This relatively recent date of graduation 
for the responding population are unlikely to fully represent the 
average age of the total population of practicing family practice 
physicians in the United States. Comparatively, the mean year of 
graduation among the subspecialist immunologists was 1978.
Overall, we hypothesized that treatment practices may reflect 
introduction to PID in medical school or post-medical school 
training; therefore, we sought to discern the level of coverage. The 
majority (76%) of family practice physicians reported that PID 
was covered “only a little” in medical school, with 11% respond-
ing that PID was not covered at all and 12% indicating that PID 
was “adequately” covered (Table  1). Exposure beyond medical 
school training was limited among family practice physicians in 
this survey, with 99% reporting that they have not heard a lecture 
regarding PID identification and diagnosis in the last 6 months, 
despite more than half (66%) believing such a lecture would be 
beneficial. The lack of sufficient PID exposure and training in 
medical school and beyond may indicate a specific inefficiency in 
education programs related to PID, where significant improve-
ments could be easily achieved.
clinical experience with PiD among 
respondents
Given the emerging data that indicate PID prevalence is likely 
underestimated (6–9) and that recent United States popula-
tion estimates common variable immunodeficiency (CVID) 
occurs in 1:2400 persons (6), these patients should statistically 
be present in many PCP practices. In the current survey, 1% 
of family practice physicians reported following five or more 
patients with a PID diagnosis, whereas approximately half (56%) 
reported that they had not followed any. Although CVID is the 
most commonly occurring PID (6, 21, 27), significantly fewer 
responding family practice physicians (9%) reported following 
at least one patient with this diagnosis, compared with 99% of 
subspecialist immunologists (P < 0.05) (Figure 1). Subspecialist 
immunologists also reported that they had followed patients with 
diagnoses that were rarely reported as present in family physi-
cian practices. Selective immunoglobulin A (IgA) deficiency 
(21%) and chronic granulomatous disease (CGD) (11%) were 
the most common diagnoses followed among family practice 
physicians who reported following at least one patient with PID. 
As expected, both diagnoses were significantly more prevalent 
among the practices of subspecialist immunologists (96% IgA 
and 89% CGD; P < 0.05 for each).
FigUre 1 | Percentage of family practice physicians, compared with subspecialist immunologists, who have ever followed patients with a PiD. 
*P < 0.0001. AT, ataxia telangiectasia; CGD, chronic granulomatous disease; CMC, chronic mucocutaneous candidiasis; CVID, common variable immunodeficiency; 
IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; PID, primary immunodeficiency disease; SAD, selective antibody deficiency; SCID,  
severe combined immunodeficiency; WAS, Wiskott–Aldrich syndrome; XLA, X-linked agammaglobulinemia (Bruton’s agammaglobulinemia).
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clinical Management of PiD among 
respondents
A substantial gap exists in the awareness of professional guide-
lines for the diagnosis and management of PID (13, 28) between 
family practice physicians and subspecialist immunologists. 
Four percent of family practice physicians were aware of these 
guidelines, compared with 79% of subspecialist immunologists 
(P < 0.05). Although this level of expertise for the treatment of 
PID is not expected outside the specialty of immunology, this 
substantial difference underlies the importance of initiatives that 
strive to promote awareness among physicians who participate in 
the care of patients with PID.
The majority (77%) of family practice physicians reported that 
they were not at all comfortable with recognizing and diagnos-
ing PID, and none indicated complete comfort in recognizing 
and diagnosing among the group of disorders. However, 22% 
reported being “somewhat” comfortable. Forty percent of fam-
ily practice physicians reported that if they suspect a patient to 
have an underlying PID, they will refer the patient to a specialist 
(including specialists in the field of allergy, immunology, and 
hematology). Similar proportions will order tests (26%) or will 
order tests and also refer the patient to a specialist (23%); only 6% 
reported that they had independently diagnosed a patient with 
PID. The most commonly ordered diagnostic tests in pursuit of 
a PID diagnosis among PCP family practice physicians included 
quantitative serum Ig (84%), serum immunoelectrophoresis 
(65%), and a complete blood count with manual differential 
(62%) (Figure 2). Recent recommendations advise against testing 
for IgG subclasses when PID is suspected (29) and question its 
clinical relevance (30). However, 22% of family practice physi-
cians still use it as a diagnostic approach, underlying a potential 
gap in patient management that has gained some primary care 
focus through the ABIM Choosing Wisely initiative.
Use of ig replacement for PiD
A small proportion (5%) of family practice physicians reported 
being the primary treatment provider for patients with PID. 
Replacement therapy with various intravenously (IV)- and subcu-
taneously (SC)-administered preparations of Ig (IVIG and SCIG, 
respectively) is approved by the United States Food and Drug 
Administration and commonly used for the treatment of patients 
with PID (28). While nearly all subspecialist immunologists who 
treat patients with PID commonly recommend IVIG therapy 
for their patients with Bruton’s agammaglobulinemia (X-linked 
agammaglobulinemia; XLA), CVID, hyper IgM syndrome (hyper 
IgM), and severe combined immunodeficiency disease (SCID), 
significantly fewer family practice physicians recommended IVIG 
therapy for these same diagnoses: XLA, 100 vs. 71% (P < 0.05); 
CVID, 98 vs. 42% (P < 0.05); hyper IgM, 92 vs. 23% (P < 0.05), 
and SCID, 92 vs. 75% (P < 0.05) (Figure 3). Furthermore, 65% 
of prescribing family practice physicians believed that IVIG 
therapy was only a somewhat-effective treatment approach for 
patients with antibody deficiency disorders. The majority (90%) 
reported that they were not too familiar with SCIG; however, this 
is not unexpected, considering SCIG was only granted approval 
in the United States in 2006 (31) and its use among subspecialist 
immunologists still continues to expand. As such, 93% of family 
practice physicians who recommended Ig therapy for patients 
FigUre 3 | Percentage of family practice physicians, compared with subspecialist immunologists, recommending iVig therapy for all or most 
patients with a diagnosis of a specific PiD (in at least some patients within the listed diagnosis). *P < 0.0001; †P = 0.006. CGD, chronic granulomatous 
disease; CVID, common variable immunodeficiency; IgA, immunoglobulin A; IgG Sub, immunoglobulin G subclass; IgM, immunoglobulin M; IVIG, intravenously 
administered immunoglobulin; PID, primary immunodeficiency disease; SCID, severe combined immunodeficiency; XLA, X-linked agammaglobulinemia (Bruton’s 
agammaglobulinemia).
FigUre 2 | Percentage of family practice physicians ordering specific tests for the diagnosis of PiD. Anti-Pneumo titer, anti-Pneumococcal titer; CBC, 
complete blood count; CH50, hemolytic complement; CT, computed tomography; DTH, delayed-type hypersensitivity; IgG, immunoglobulin G; PID, primary 
immunodeficiency disease; QIgs, quantitative serum; SPEP, serum immunoelectrophoresis.
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with PID indicated that they use primarily IVIG (primarily in an 
outpatient setting). Narrowing the gap in the prescribing patterns 
of Ig replacement and awareness of administration options may 
improve disease management for patients with PID.
Use Vaccines in Patients with PiD
Application of vaccines and the subsequent antibody response 
can indicate functional capacity of the immune system, and 
this assessment, although complex, can facilitate PID diagnosis. 
However, the use of live viral vaccines needs to be excluded in 
certain immunodeficiencies (14). These patients sometimes fail 
to produce a quality response to vaccines or are susceptible to 
harm from live vaccines (14, 32–35). Given the frequent use 
of vaccines by family practice physicians, this was viewed as 
an especially relevant topic. Family practice physicians recom-
mended avoidance of live vaccines across a variety of PIDs 
FigUre 4 | Percentage of family practice physicians, compared with subspecialist immunologists, avoiding live vaccines for patients with specific 
PiD. *P < 0.0001. Ab, antibody; CGD, chronic granulomatous disease; CVID, common variable immunodeficiency; IgA, immunoglobulin A; IgG, immunoglobulin G; 
IgM, immunoglobulin M; PID, primary immunodeficiency disease; SAD, selective antibody deficiency; SCID, severe combined immunodeficiency; WAS, 
Wiskott– Aldrich syndrome; XLA, X-linked agammaglobulinemia (Bruton’s agammaglobulinemia).
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(Figure 4). Significantly, more subspecialist immunologists than 
family practice physicians recommended avoidance of live viral 
vaccines for DiGeorge syndrome (61 vs. 26%, P < 0.05), hyper 
IgM (52 vs. 17%, P <  0.05), and Wiskott–Aldrich syndrome 
(57 vs. 23%, P < 0.05). There is an educational opportunity for 
family practice physicians regarding the potential risks of certain 
vaccines to patients with PID consistent with the prescriber 
information labels that contraindicate live viral vaccine use in 
PID, which could reduce the risk of complications in patients 
with certain PIDs.
DiscUssiOn
This survey questioned family practice physicians practicing in 
the United States to assess their awareness of PID, along with the 
identification, diagnosis, and management of patients with these 
diseases. Evaluating routine practices and standards of care across 
a spectrum of physicians (e.g., pediatricians, family practice 
physicians, allergists, pulmonologists, and infectious disease spe-
cialists) who frequently encounter patients with PID may reveal 
opportunities in which dissemination of knowledge (e.g., PID 
recognition and diagnosis) may be useful. For example, a recent 
survey of pediatricians revealed that while 77% followed at least 
one patient with PID, over one-third (35%) were uncomfortable 
with PID recognition and diagnosis (26). Recommendations tar-
geting other specialists, including pulmonologists, pathologists, 
and gastroenterologists, have already been published to raise 
awareness of the signs of undiagnosed PID (20, 36, 37). Family 
practice physicians may likewise benefit from similar educational 
initiatives. Therefore, the results of the current survey were 
compared with survey responses from subspecialist immunolo-
gists (23) to determine which areas need to be highlighted when 
developing educational materials. Given the appropriately diverse 
clinical interests of family practitioners, however, perhaps the 
most important message of our study is the potential benefits 
in aligning with immunology consultants when the question of 
PID arises. Recognizing PID is perhaps the hardest part of the 
equation, and the fact that so many family practice physicians had 
knowledge of patients and the diagnoses is enabling. The ability 
to identify and collaborate with clinical immunologists should be 
able to provide important steps in ensuring best practices within 
this rare disease population.
In the current survey, family practice physicians were gener-
ally not completely comfortable identifying and diagnosing PID, 
even though they will likely encounter a range of PIDs over the 
course of their practice. Interestingly, only 44% reported that 
they had followed a patient with a PID diagnosis. Given the 
emerging prevalence data that indicate PIDs are more common 
than once believed (3, 4, 6, 27) along with estimates of how many 
new patients a family practice physician might encounter over 
the duration of their practice, responses regarding diagnoses fol-
lowed likely suggest that there are undiagnosed patients.
For some of the more serious diseases, onset occurs during 
infancy or childhood (2). However, PIDs affect all age groups 
and are more common in older patients than originally believed 
(38–40). Given that some PIDs, including CVID, CGD, and 
complement deficiencies, can be present during adulthood (27), 
family practice physicians may need to recognize and diagnose 
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a more adult and elderly patient population. Indeed, in a 2008 
survey of 1250 PCPs, 400 (32%) of the overall respondents [144 
of 250 (58%) pediatricians, 148 of 490 (30%) internists and 108 
of 510 (21%) family practice physicians] indicated that they had 
diagnosed, treated, or referred a patient with PID within the 
previous 5 years (41).
Patients with PID often present with increased occurrence of 
severe, persistent, and recurrent infections, autoimmunity, inflam-
mation, allergy, and malignancies, which are associated with sup-
pressed or inadequate immune function (1, 2, 16). These diseases 
are chronic, lifelong conditions requiring ongoing treatment and 
management. In a national survey of more than 1500 patients with 
PID, only 30% reported that they did not experience any degree of 
limitation in work, play, or normal physical activity because of their 
health (42). Current activity limitation and health status rating are 
both strongly influenced by permanent functional impairments 
that can occur prior to diagnosis (42). Patients often suffer from a 
significant time lag between symptom onset and the time of PID 
diagnosis (43–46). For all PID diagnoses, the average time from 
symptom onset to diagnosis has been reported to be 12.4  years 
(19). In the period preceding diagnosis, 54% reported developing 
a permanent functional impairment including, but not limited to, 
a decline in lung function, digestive function, and hearing (24).
Prevention of serious infections with timely intervention can 
improve patient outcome and quality of life following initiation of 
treatment (47, 48). Although treatment of PID is usually guided 
by an immunologist, a small number of family practice physi-
cian respondents actively manage IgG treatment for any patient 
(n =  4). Only a minority (15%) of family practice physicians 
who utilize IVIG therapy believed it to be very effective in the 
treatment of patients with PID. Because of the small number of 
responses regarding treatment management, results of the cur-
rent survey do not provide adequate information regarding the 
dosages and intervals of dosing being used in the clinic by family 
practice physicians. In PID cases for which a family practice phy-
sician is the primary treating physician, knowledge of the most 
current treatment guidelines would ensure that patients receive 
the proper standard of care.
Surveys of this nature are always subject to non-response bias. 
The high proportion of non-responders could have been influ-
enced by the fact that PID is considered to be rare (4); however, 
response rates were similar to those of the subspecialist immu-
nologists (23). In an effort to increase response rates, two survey 
mailings were done and a financial incentive was offered to those 
who responded. Responses were kept anonymous in an attempt 
to reduce responder bias. A minimal amount of response bias 
has been shown in relation to survey responses among physicians 
(49, 50). That said, this work represents the first national survey 
of family practice physicians with regards to PID and suggest 
numerous opportunities with which diagnosis and care can be 
enhanced.
The present survey underscores the opportunity to improve 
education and training initiatives during medical school and in 
residency. Because notable differences exist in the way family 
practice physicians and general or subspecialist immunologists 
diagnose and manage patients with PID, it is relevant to continue 
efforts to increase awareness surrounding PID. The survey pro-
vides rationale supporting further initiatives designed to increase 
awareness and knowledge about PID among family practice 
physicians. The ability to consider and recognize PID patients is 
a critical task, which offers tremendous opportunity for a family 
practitioner to improve expected patient outcomes. This can 
only be improved further and linked directly to best practices for 
patients through education and collaboration with subspecialists 
in this increasingly complex field.
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